Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 18, 2022

Effect of SGLT2 Inhibitors on Kidney and CV Events in Patients With Advanced Diabetic Kidney Disease

Diabetes Research and Clinical Practice


Additional Info

Diabetes Research and Clinical Practice
SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study
Diabetes Res. Clin. Pract. 2023 Jan 01;195(xx)110200, G Chun-Kau Chan, J Kit-Chung Ng, KM Chow, CC Szeto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading